Composition for suppressing increase in triglyceride in blood

Abstract

To provide a composition for suppressing an increase in triglyceride in blood, the composition having a dramatically improved effect of suppressing the increase in triglyceride in blood.SOLUTION: Provided is a composition for suppressing an increase in triglyceride. The composition comprises indigestible dextrin as an active ingredient. The composition further comprises one or more amino acids selected from alanine and valine.SELECTED DRAWING: Figure 3

Description

[Technical Field]

[0001] The present invention relates to a composition for suppressing an increase in neutral fat in blood, and more particularly to a composition for suppressing an increase in neutral fat in blood, which contains indigestible dextrin and other specific ingredients as active ingredients. [Background technology]

[0002] Resistant dextrin is known to have various functions for regulating the body, one of which is its ability to suppress the elevation of blood triglycerides. However, this effect alone is not necessarily sufficient.

[0003] On the other hand, with regard to the functions of resistant dextrin, for example, an IgA secretion promoter containing resistant dextrin as an active ingredient (see Patent Document 1) and a blood cresol-lowering agent for patients with renal failure containing resistant dextrin as an active ingredient (see Patent Document 2) have been proposed. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Laid-Open No. 2014-152125 [Patent Document 2] Japanese Patent Application Laid-Open No. 2014-148467 Summary of the Invention [Problem to be solved by the invention]

[0005] An object of the present invention is to provide a composition for inhibiting an increase in neutral fat in blood, which has a dramatically improved effect of inhibiting an increase in neutral fat in blood. [Means for solving the problem]

[0006] The present inventors have conducted extensive research and studies into the inhibitory effect of resistant dextrin on the elevation of neutral fats in the blood, and have found that the inhibitory effect on the elevation of neutral fats in the blood can be dramatically improved by combining resistant dextrin with a specific component, thereby completing the present invention. Specifically, they have found that by combining resistant dextrin with a component that has little or only a small inhibitory effect on the elevation of neutral fats in the blood, the inhibitory effect on the elevation of neutral fats in the blood can be dramatically improved compared to the case of resistant dextrin alone.

[0007] That is, the present invention relates to a composition for suppressing elevation of blood triglycerides, characterized by containing, as active ingredients, indigestible dextrin and at least one component selected from the group consisting of pine bark extract, processed young barley leaves, collagen, pectin, tannin, alanine, valine, vitamin A, vitamin B1, niacin, sodium pantothenate, vitamin E, and selenium compounds.

[0008] The composition for suppressing elevation of blood neutral fat of the present invention may be obtained by adding an active ingredient.

[0009] In the composition for suppressing an increase in blood neutral fat of the present invention, the blending mass ratio of the indigestible dextrin to the other active ingredient(s) is preferably in the range of 0.5:1 to 70:1. Furthermore, the composition for suppressing elevation of blood neutral fat of the present invention is preferably in the form of a tablet, capsule, powder, granule, or liquid.

[0010] The present invention also relates to a method for suppressing an increase in blood neutral fat (excluding medical procedures), which comprises ingesting the composition for suppressing an increase in blood neutral fat of the present invention. [Effects of the Invention]

[0011] The composition for suppressing an increase in neutral fat in blood of the present invention can dramatically improve the effect of suppressing an increase in neutral fat in blood compared to the case where indigestible dextrin is used alone. [Brief explanation of the drawings]

[0012] [Figure 1] FIG. 1 shows the concentration of triglycerides (TG) secreted after absorption into Caco-2 monolayer membranes when the composition for suppressing elevation of blood neutral fats of the present invention was applied, and shows the results when pine bark extract was used together with indigestible dextrin. [Figure 2] FIG. 1 shows the concentration of triglycerides (TG) secreted after absorption into Caco-2 monolayer membranes when the composition for suppressing elevation of blood neutral fats of the present invention was applied, and shows the results when young barley leaves, collagen, pectin, and tannic acid were used together with indigestible dextrin. [Figure 3] FIG. 1 shows the concentration of triglycerides (TG) secreted after absorption into Caco-2 monolayer membranes when the composition for suppressing elevation of blood neutral fats of the present invention was applied, and shows the results when alanine was used together with indigestible dextrin. [Figure 4] FIG. 1 shows the concentration of triglycerides (TG) secreted after absorption into Caco-2 monolayer membranes when the composition for suppressing elevation of blood neutral fats of the present invention was applied, and shows the results when valine was used together with indigestible dextrin. [Figure 5] FIG. 1 shows the concentration of triglycerides (TG) secreted after absorption into Caco-2 monolayer membranes when the composition for suppressing elevation of blood neutral fats of the present invention was applied, and shows the results when vitamin A was used together with indigestible dextrin. [Figure 6] FIG. 1 shows the concentration of triglycerides (TG) secreted after absorption into Caco-2 monolayer membranes when the composition for suppressing elevation of blood neutral fats of the present invention was applied, and shows the results when vitamin B1, niacin, and sodium pantothenate were used together with indigestible dextrin. [Figure 7] FIG. 1 shows the concentration of triglycerides (TG) secreted after absorption into Caco-2 monolayer membranes when the composition for suppressing elevation of blood neutral fats of the present invention was applied, and shows the results when vitamin E was used together with indigestible dextrin. [Figure 8]FIG. 1 shows the concentration of triglycerides (TG) secreted after absorption into Caco-2 monolayer membranes when the composition for inhibiting elevation of blood neutral fats of the present invention was applied, and shows the results when a serine compound (sodium selenite) was used together with indigestible dextrin. DETAILED DESCRIPTION OF THE INVENTION

[0013] The composition for suppressing elevation of blood triglycerides of the present invention is characterized by containing, as active ingredients, indigestible dextrin and at least one component (hereinafter sometimes referred to as "other component") selected from the group consisting of pine bark extract, processed young barley leaves, collagen, pectin, tannin, alanine, valine, vitamin A, vitamin B1, niacin, sodium pantothenate, vitamin E, and selenium compounds.

[0014] [Indigestible dextrin] The resistant dextrin, which is the active ingredient of the composition for suppressing elevation of blood neutral fat levels of the present invention, is a resistant polysaccharide that is resistant to hydrolysis by human digestive enzymes (amylases). For example, it can be obtained by hydrolyzing starch by heating, followed by hydrolysis with amylase, and purifying the resistant component. This resistant dextrin is commercially available in the form of powder, fine granules, granules, etc., and these commercially available products can be used. Furthermore, since resistant dextrin is water-soluble, it may also be used in the form of an aqueous solution.

[0015] [Other ingredients] (pine bark extract) Examples of pine species that can be used as raw materials for pine bark extract include French maritime pine (Pinus Martima), larch, black pine, and red pine. Among these, French maritime pine (Pinus Martima), which is rich in proanthocyanidins, is preferred. The extract can be obtained by extraction using an appropriate solvent, and examples of the solvent that can be used include water (hot water, warm water), ethanol, and aqueous ethanol. In addition to proanthocyanidins, the extract contains oligomeric proanthocyanidins at high concentrations, and preferably contains oligomeric proanthocyanidins in an amount of 20% by mass or more based on the dry mass of the extract.

[0016] (Processed barley leaves) As the barley used as the raw material for the processed young barley leaf product, two-row barley, six-row barley, etc. can be used. As the processed young barley leaf product, processed products such as pulverized young barley leaves, juice, extracts, etc. can be used. Examples of pulverized products include powder and granules. The juice and extract may be in liquid form, but can also be used as a paste or dry powder. The extract can be obtained by extraction using an appropriate solvent, and examples of the solvent that can be used include water (hot water, warm water), ethanol, and aqueous ethanol.

[0017] (collagen) Collagen may be animal-derived or synthetic, and includes collagen protein, collagen peptide obtained by hydrolyzing collagen protein, and atelocollagen obtained by treating collagen molecules with protease to remove telopeptide portions. Collagen derived from fish is particularly preferred as animal-derived collagen. The average molecular weight (weight-average molecular weight) of collagen is not particularly limited, but is preferably 500 to 100,000, and more preferably 1,000 to 50,000.

[0018] (pectin) The pectin may be plant-derived pectin or synthetic pectin. Examples of plant-derived pectin include extracts from fruits such as apples and citrus fruits, and vegetables. Pectin is classified into HM pectin, which has a high degree of esterification, and LM pectin, which has a low degree of esterification, and either type of pectin may be used. In addition, commercially available pectins used as gelling agents, thickeners, etc. may be used.

[0019] (tannins) The tannin may be a hydrolyzable tannin or a condensed tannin, and examples thereof include extracts obtained from persimmon fruit, chestnut astringent skin, Chinese gallnut, tamarind seed coat, tarragon powder, gall nuts, and mimosa bark. 76 H 52 O 46 ) can be used.

[0020] The composition for inhibiting elevation of blood triglycerides of the present invention is preferably a blood triglyceride elevation inhibitor used for inhibiting elevation of blood triglycerides. Such a blood triglyceride elevation inhibitor is not particularly limited as long as it contains indigestible dextrin and other specified ingredients and can be distinguished from other products in terms of its use in inhibiting elevation of blood triglycerides. For example, the scope of the present invention includes products that display an indication of their blood triglyceride elevation inhibitory effect on the product itself, packaging, instructions, or promotional materials. Examples of such products include so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods such as specified health foods, nutritional functional foods, and functional food products whose efficacy has been recognized by a designated organization, as well as feed. Examples of so-called health foods include those labeled with claims such as "inhibits elevation of triglycerides," "for those concerned about triglycerides," "inhibits fat absorption," and "for those with high triglycerides." These health foods may be taken separately from meals, but are preferably taken at the time of a meal. For example, it is preferable to take them between 1 hour before and 1 hour after a meal, more preferably between 0.5 hours before and 0.5 hours after a meal, and even more preferably between 0.5 hours before and at the start of a meal or during a meal.

[0021] Examples of the form of the composition for suppressing elevation of blood neutral fat of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, pills, pastes, creams, caplets, gels, chewable tablets, and sticks. Among these, tablets, capsules, powders, granules, and liquids are particularly preferred. Specific examples include supplements, packaged beverages filled in PET bottles, cans, jars, etc., and instant powdered beverages and instant granular beverages that can be dissolved in water (hot water), milk, fruit juice, green juice, etc. for consumption. These are preferred because they are easy to drink during meals and can be more palatable.

[0022] The content of indigestible dextrin and other ingredients (active ingredients) in the composition for suppressing elevation of blood neutral fat of the present invention may be appropriately determined within the range in which the effect is exhibited.

[0023] Generally, when the composition for suppressing elevation of blood neutral fat of the present invention is a pharmaceutical or supplement (tablet, capsule), the active ingredient is preferably contained in an amount of 0.01 to 100 mass% of the total, calculated on a dry mass basis, more preferably 0.1 to 85 mass%, and even more preferably 0.5 to 70 mass%.

[0024] When the composition for suppressing elevation of blood neutral fat of the present invention is a packaged beverage (liquid), the active ingredient is preferably contained in an amount of 0.1 to 10 mass % of the total amount, calculated as dry mass, more preferably 0.3 to 6 mass %, and even more preferably 0.5 to 4 mass %.

[0025] Furthermore, when the composition for inhibiting elevation of blood neutral fats of the present invention is an instant powdered drink (powder) or an instant granular drink (granules), the active ingredient is preferably contained in an amount of 10 to 100% by mass, more preferably 50 to 100% by mass, and even more preferably 80 to 100% by mass, of the total amount converted to dry mass.

[0026] In order to particularly effectively exert the effects of the present invention, the active ingredient is preferably contained in an amount of 80% by mass or more of the entire composition for inhibiting elevation of blood triglycerides of the present invention (excluding water) converted into dry mass, more preferably 90% by mass or more, even more preferably 95% by mass or more, and particularly preferably 100% by mass.

[0027] There are no particular restrictions on the intake amount of the composition for suppressing elevation of blood triglycerides of the present invention, but from the viewpoint of more significantly exerting the effects of the present invention, it is preferable to take so that the daily intake of the active ingredient is 500 mg / day or more, more preferably 1 g / day or more, even more preferably 2 g / day or more, and particularly preferably 4 g / day or more.

[0028] The composition for suppressing an increase in blood neutral fat of the present invention can be stored as a daily dose in one container or divided into, for example, 2 to 3 containers so that the daily intake will be the above-mentioned amount.

[0029] Furthermore, the composition for suppressing an increase in blood triglycerides of the present invention may be taken separately from a meal, but since it can particularly effectively suppress a transient increase in blood triglycerides after a meal, it is preferable to take it at the time of a meal. For example, it is preferable to take it between 1 hour before a meal and 1 hour after a meal, more preferably between 0.5 hours before a meal and 0.5 hours after a meal, and even more preferably to take it between 0.5 hours before a meal and the start of a meal or during a meal.

[0030] The blending mass ratio of the indigestible dextrin to the other ingredients, calculated on a dry mass basis, is preferably in the range of 0.5:1 to 70:1, more preferably in the range of 0.75:1 to 60:1, even more preferably in the range of 1:1 to 60:1, and particularly preferably in the range of 1:1 to 50:1. When the blending ratio of the indigestible dextrin to the other ingredients is in the above range, the effects of the present invention can be more effectively exhibited.

[0031] The composition for suppressing elevation of blood neutral fat of the present invention can be produced by known formulation methods, adding ingredients other than the orally acceptable active ingredient, as needed.

[0032] Furthermore, examples of the composition for suppressing elevation of blood triglycerides of the present invention include not only compositions containing an active ingredient but also compositions for suppressing elevation of blood triglycerides (foods for suppressing elevation of blood triglycerides) obtained by adding the active ingredient to a food. For example, foods containing an increased amount of the active ingredient of the present invention compared to ordinary foods (including natural foods) and foods in which the active ingredient of the present invention has been added to foods that do not normally contain the active ingredient of the present invention are included. Furthermore, in order to more effectively exert the effects of the present invention, the composition for suppressing elevation of blood triglycerides of the present invention is preferably a high-fat food for suppressing elevation of blood triglycerides obtained by adding the active ingredient to a high-fat food with a fat content of 10% by mass or more, preferably 20% by mass or more. The active ingredients may be added separately or simultaneously, or together with other ingredients other than the active ingredient.

[0033] Examples of the food for suppressing an increase in blood neutral fat of the present invention include beverages such as carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juice; frozen desserts such as ice cream, ice sherbet, and shaved ice; noodles such as soba, udon, harusame, Chinese noodles, and instant noodles; sweets such as candy, candy, gum, chocolate, tablet sweets, snacks, biscuits, jelly, jam, cream, baked goods, and bread; processed seafood and livestock foods such as kamaboko, ham, and sausage; processed milk, dairy products, and dairy products. Examples include dairy products such as fermented milk and yogurt; oils and fats such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream and dressing, and processed foods thereof; seasonings such as sauces and soy sauce; and retort pouch foods such as curry, stew, oyakodon, rice porridge, rice porridge, Chinese rice bowl, katsudon, tempura bowl, beef bowl, hayashi rice, omelet rice, oden, mapo dolphin, gyoza, shumai, hamburger steak, meatballs, various sauces and various soups.

[0034] The method for suppressing an increase in blood triglyceride levels of the present invention is characterized by ingestion of the composition for suppressing an increase in blood triglyceride levels of the present invention described above, but does not include medical procedures. The composition for suppressing an increase in blood triglyceride levels of the present invention may be ingested separately from a meal, but is preferably ingested at the time of a meal, since it is particularly effective in suppressing transient increases in blood triglyceride levels after meals. For example, it is preferably ingested between 1 hour before and 1 hour after a meal, more preferably between 0.5 hours before and 0.5 hours after a meal, and even more preferably between 0.5 hours before and the start of a meal or during a meal. An example of the method of the present invention is a method for suppressing an increase in blood triglyceride levels in a restaurant or other eating establishment by providing the composition for suppressing an increase in blood triglyceride levels of the present invention together with high-fat foods. [Example]

[0035] The present invention will be described below based on examples. [Example 1] The inhibition of neutral fat absorption (inhibition of blood neutral fat elevation) was evaluated using a Caco-2 monolayer membrane absorption and secretion test using human colon cancer-derived cells. Caco-2 cells are known to differentiate into intestinal epithelium-like cells when cultured, and intestinal absorption can be evaluated by measuring the amount of substance permeation through the Caco-2 monolayer membrane.

[0036] 1. Sample Preparation The solution was adjusted to 0.2 mM lysophosphatidylcholine, 0.1 mM oleic acid, 0.1 mM 2-monooleoylglycerol, and 2 mM sodium taurodeoxycholate, and sonicated to produce micelles of 300-500 nm.

[0037] The micelles prepared above and a test substance (resistant dextrin alone, or resistant dextrin plus other components shown in Table 1) were added to DMEM and adjusted to the desired final concentration.

[0038] 2. Caco-2 monolayer absorption and secretion test 100 μL of sample was added to the insert well of the Caco-2 monolayer membrane and incubated in a 37°C, 5% CO2 incubator. After 24 hours, 600 μL of the solution on the basement membrane side was collected, and 200 μL of CHCl3:MeOH (2:1) was added. The mixture was vortexed and centrifuged. The lower layer (organic layer) was collected, and 200 μL of CHCl3:MeOH (2:1) was added again. The mixture was vortexed and centrifuged. The lower layer (organic layer) was collected, and the organic layer was dried. 20 μL of 2-propanol was added, and triglyceride (TG) was measured. TG measurements were performed using a Wako kit (Triglyceride E-Test Wako).

[0039] The results are shown in Table 1 and Figures 1 to 8. In each graph in the figure, for the control (resistant dextrin), "-" indicates no addition, "+" indicates the addition of 200 μg / mL of resistant dextrin alone. Furthermore, for those showing other ingredients, "-+" indicates the addition of the other ingredient alone, and "++" indicates the addition of 200 μg / mL of resistant dextrin plus the other ingredient.

[0040] [Table 1]

[0041] As the indigestible dextrin, commercially available indigestible dextrin powder was used. For the barley leaves, dried and crushed powder was used. For pine bark, a hot water extract (dried powder) of French maritime pine bark was used. For young sweet potato leaves, dried and crushed powder was used.

[0042] As shown in Table 1 and Figures 1 to 8, the combination of indigestible dextrin with the specific other components of the present invention synergistically reduced the amount of fat passing through the Caco-2 monolayer membrane. Therefore, it can be seen that the composition for suppressing an increase in blood neutral fat of the present invention can effectively suppress an increase in blood neutral fat.

[0043] [Example 2] (Production of tablets) The ingredients were mixed in the proportions shown below and tableted using a tablet press.

[0044] Ingredients Composition (mg) Indigestible dextrin 135 Barley grass powder 150 Excipients 120 Vitamin B1 15 Anhydrous Citric Acid 15 Alanine 10 Balin 10

[0045] It is expected that taking a few tablets of this tablet per day will have the effect of suppressing the increase in blood neutral fat levels.

[0046] [Example 3] (Production of capsules) The ingredients were mixed in the proportions shown below and made into granules in a conventional manner, and 250 mg of the granules were filled into capsules to prepare capsules. Ingredients Weight part Indigestible dextrin 15 Pine bark extract 1 Collagen 1 Vitamin E 0.1 Excipients 5

[0047] It is expected that taking a few capsules of this capsule per day will have the effect of suppressing the rise in blood neutral fat levels.

[0048] [Example 4] (Production of Granules) The ingredients were mixed in the proportions shown below and made into granules in a conventional manner, and 800 mg of the granules were packaged in aluminum sticks. Ingredients Weight part Indigestible dextrin 15 Barley grass 1 Excipients 5 Anhydrous citric acid 0.1 Tannic acid 0.01

[0049] By taking, for example, several packets of this granule per day, it is expected that the effect of suppressing the increase in blood neutral fats can be obtained.

[0050] [Example 5] (Production of liquid formulation) A liquid formulation was prepared by filling a container with 1 part by weight of pine bark extract, 5 parts by weight of barley leaf powder, 3 parts by weight of 15 parts by weight of indigestible dextrin hydrolyzed collagen, an appropriate amount of vitamin C, and 200 ml of water and sealing it. [Industrial Applicability]

[0051] The composition for suppressing an increase in blood neutral fat of the present invention has the effect of suppressing an increase in blood neutral fat, and is therefore highly useful industrially.

Claims

[Claim 1] The composition for suppressing an increase in neutral fat contains indigestible dextrin and one or more vitamins selected from vitamin B1, sodium pantothenate, and vitamin E.

Images